The pharmaceutical community is excited by retatrutide, a novel dual GIP and GLP-1 receptor that’s showing impressive results in clinical trials . This treatment works by imitating natural hormones to affect appetite and boost feelings of fullness , ultimately leading noticeable body decrease. While currently under evaluation and not readily avai